华大基因：前三季度亏损2138.7万元 同比减亏

Core Viewpoint - BGI Genomics (300676) reported a revenue of 1.042 billion yuan in Q3 2025, marking a year-on-year increase of 9.19%, while the net profit attributable to shareholders was a loss of 27.1652 million yuan, compared to a loss of 142 million yuan in the same period last year [1] Summary by Sections Financial Performance - In Q3 2025, the company achieved a revenue of 1.042 billion yuan, reflecting a 9.19% increase year-on-year [1] - The net profit attributable to shareholders for Q3 2025 was a loss of 27.1652 million yuan, an improvement from a loss of 142 million yuan in Q3 2024 [1] - For the first three quarters of 2025, the total revenue was 2.674 billion yuan, which represents a year-on-year decline of 5.39% [1] - The net profit attributable to shareholders for the first three quarters of 2025 was a loss of 21.387 million yuan, compared to a loss of 124 million yuan in the same period last year [1]